 |
|
Evaluating the Long-Term Need for Antiparkinson Drugs by Chronic Schizophrenics
C. James Klett, PhD;
Perry Point, Md;
Eugene Caffey, Jr., MD
Arch Gen Psychiatry. 1972;26(4):374-379.
Abstract
Chronic schizophrenic males receiving both antipsychotic and antiparkinson medication had the latter replaced by placebo for a sixweek study period. To provide a double-blind control, a smaller group received matching tablets of benztropine mesylate. Of 403 patients receiving placebos, 7% were withdrawn from the study because of substantial return or appearance of extrapyramidal symptoms. Another 11% were judged to be worse from the rating scale data, but the remaining 82% seemed to get along quite well without antiparkinson medication, experiencing at most some temporary symptoms of extrapyramidal system disturbance. From these and other data, it is recommended that clinicians reconsider their prescribing habits, particularly prophylactic and long-term use of antiparkinson drugs.
Author Affiliations
Washington, DC
From the Central Neuropsychiatric Research Laboratory, Veterans Administration Hospital, Perry Point, Md, (Dr. Klett) and the Veterans Administration Central Office, Washington, DC (Dr. Caffey).
Footnotes
Accepted for publication July 6, 1971.
Reprint requests to Central NP Research Laboratory, Veterans Administration Hospital, Perry Point, Md 21902 (Dr. Klett).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Hospital Surveys of Prescribing Practices With Psychotherapeutic Drugs: A Critical Examination
Prien et al.
Arch Gen Psychiatry 1978;35:1271-1275.
ABSTRACT
Are Prophylactic Antiparkinson Drugs Necessary? A Controlled Study of Procyclidine Withdrawal
Rifkin et al.
Arch Gen Psychiatry 1978;35:483-489.
ABSTRACT
Dopamine Excretion and Vulnerability to Drug-Induced Parkinsonism: Schizophrenic Patients
Crowley et al.
Arch Gen Psychiatry 1978;35:97-104.
ABSTRACT
|
